Compare AGIO & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGIO | CERT |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | 1546 |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2013 | 2020 |
| Metric | AGIO | CERT |
|---|---|---|
| Price | $26.97 | $8.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | ★ $32.13 | $13.88 |
| AVG Volume (30 Days) | ★ 2.7M | 2.0M |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $44,791,000.00 | ★ $415,551,000.00 |
| Revenue This Year | $28.75 | $10.82 |
| Revenue Next Year | $139.45 | $6.77 |
| P/E Ratio | ★ N/A | $126.84 |
| Revenue Growth | ★ 36.26 | 11.47 |
| 52 Week Low | $22.24 | $8.03 |
| 52 Week High | $46.00 | $15.69 |
| Indicator | AGIO | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 38.27 |
| Support Level | $26.80 | $8.95 |
| Resistance Level | $28.61 | $9.42 |
| Average True Range (ATR) | 1.15 | 0.39 |
| MACD | 0.28 | 0.06 |
| Stochastic Oscillator | 16.59 | 14.10 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.